No Detail Found!

A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease

Author(s)
Liang Zhu Department of Neurology, Xuzhou Central Hospital,Xuzhou, Jiangsu,China
Guanjin Wu Neurology Ward 2, Zhengzhou Yihe Hospital Affiliated to Henan University,Zhengzhou, Henan,China
Weiwei Heng Department of Neurology, Xuzhou Central Hospital,Xuzhou, Jiangsu,China
Xuefeng Zang The Yancheng Clinical College of Xuzhou Medical University, The First people's Hospital of Yancheng,Yancheng,China
Abstract
To investigate the efficacy and safety of olanzapine, aripiprazole, and risperidone in the treatment of mental and behavioral symptoms of Alzheimer's Disease. A retrospective analysis was performed on the clinical data of 126 patients with Alzheimer's Disease from February 2018 to February 2020. The patients were divided into group A (aripiprazole, n=44), group B (olanzapine, n=42) and group C (risperidone, n=40) based on the treatment method. Remarkably differences at different time points among the three groups were observed (P<0.05). Significant differences in the Positive and Negative Syndrome Scale scores of different time points and cross-group comparison among the three groups were detected (P<0.05). The time-point comparison of BEHAVE-AD scores among the three groups indicated a remarkable difference (P<0.05). After 4 weeks of treatment, the Positive and Negative Syndrome Scale and BEHAVEAD scores of group A were lower than those of groups B and C (P<0.05). The total incidence of adverse reactions in group A was remarkably lower than in groups B and C (P<0.05). Olanzapine, aripiprazole and risperidone are effective in treating Alzheimer's disease and aripiprazole, with a better safety profile and fewer adverse reactions, is more suitable for elderly patients.
Publication Details
Page(s) 2053-2057
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S5, Year: 2021

Request the full text from PASTIC

Keywords
psychiatric and behavioral disorders, Dementia, senile, Aripiprazole, Risperidone, Olanzapine
References
.2018 .Guidelines for the diagnosis and treatment of dementia and cognitive impairment in China (2): guidelines for the diagnosis and treatment of Alzheimer's disease. Chin. Med, 98 : 971-977.
Cheng Z,Yuan Y,Han X,Yang L,Cai S,Yang F,Yu X .2019 .An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. J. Psychopharmacol., 33 : 1227-1236.
Han S,Jianhua S,Xin L S .2018 .Clinical study of aripiprazole combined with olanzapine in the treatment of senile Alzheimer's disease with mental disorders. J. cardio Cerebrovascr Dis. Integrated Trad. Chin. Weste Med, 16(22) : 3370-3372.
Hongjuan S .2020 .Comparison of the effects of aripiprazole and olanzapine in the treatment of schizophrenia. Contemp Med Forum, 18(6) : 6-108.
Junfei S,Ling W,Weina M .2019 .Effect of olanzapine and risperidone in the treatment of schizophrenia and its effect on the expression of miR137 and mir-18b in plasma. Int. J. Psychiatry., 46(2) : 252-255.
Junwei P,Xueming X,Longteng Y .2018 .Efficacy analysis of ohepin and risperidone in the treatment of schizophrenia or schizoid disorder with agitation symptoms. Jiangsu. Med, 44(4) : 466-467.
Keyong L,Feng C,Hua Z C .2017 .Effect of atypical antipsychotics on glucose metabolism in patients with dementia. Chin. PLA J. Med, 29(11) : 89-92.
Hanjun H Mingqiu L .2018 .Analysis and comparison of efficacy and safety of olanzapine and risperidone in the treatment of senile schizophrenia. Chin. J. Hosp. Pharm., 38(15) : 1648-1651.
Mukhopadhyay S,Kwatra G,Badyal D K PA .2017 .Erratum to: Role of olanzapine in chemotherapyinduced nausea and vomiting on platinum-based chemotherapy patients: A randomized controlled study. Support Care Cancer, 25(1) : 155-156.
Xingrong W .2020 .Safety comparison of olanzapine and risperidone in the treatment of elderly patients with schizophrenia. Chin. J. Med, 20(21) : 3648-3650.
Xue X,Song Y,Yu X,Fan Q,Tang J,Chen X .2018 .Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial. Med (Baltimore), 97(8) : e9786.
Yanxin B,Yuan F,Shiwei M .2018 .Clinical observation and analysis of the effects of aripiprazole, risperidone and olanzapine on glucose and lipid metabolism and body weight of patients with schizophrenia. J. Inner. Mongolia Med, 40(5) : 526-528.
Yaqing S,Zhaoyan J,Yanxiong S J .2018 .Comparison of clinical efficacy and safety of olanzapine and aripiprazole in the treatment of schizophrenia. Chin Primary Med, 25(18) : 2383-2386.
Ying W,Yanhui B,Rui J .2017 .Comparison of the efficacy of olanzapine and risperidone in the treatment of cognitive function in patients with schizophrenia. Chin. Pharm., 28(36) : 5083-5086.
Yinghuan Y,Rong S,Dehua M .2018 .Comparison of the efficacy of aripiprazole and olanzapine in the treatment of schizophrenia. J. Pract. Clin. Med, 22(23) : 122-119.
Yu D,Li D L .2018 .A control study of olanzapine combined with atorvastatin calcium in the treatment of Alzheimer's disease with psychobehavioral symptoms. J. Clin. Psychiatry, 28(3) : 193-195.
Zhihong Z and Zhibin W .2018 .Observation on the effect of aripiprazole and olanzapine in the treatment of mental and behavioral symptoms of senile dementia. Shanxi Med, 47(19) : 2338-2340.
0

Citations

0

Downloads

7

Views